TY - JOUR T1 - Modelling COVID-19 Transmission in the United States through Interstate and Foreign Travels and Evaluating Impact of Governmental Public Health Interventions JF - medRxiv DO - 10.1101/2020.05.23.20110999 SP - 2020.05.23.20110999 AU - Nita H. Shah AU - Nisha Sheoran AU - Ekta Jayswal AU - Dhairya Shukla AU - Nehal Shukla AU - Jagdish Shukla AU - Yash Shah Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/26/2020.05.23.20110999.abstract N2 - Background The first case of COVID-19 was reported in Wuhan, China in December 2019. The disease has spread to 210 countries and has been labelled as pandemic by WHO. Modelling, evaluating, and predicting the rate of disease transmission is crucial for epidemic prevention and control. Our aim is to assess the impact of interstate and foreign travel and public health interventions implemented by the United States government in response to the Covid-19 pandemic.Methods A disjoint mutually exclusive compartmental model is developed to study transmission dynamics of the novel coronavirus. A system of non-linear differential equations was formulated and the basic reproduction number R0 was computed. Stability of the model was evaluated at the equilibrium points. Optimal controls were applied in the form of travel restrictions and quarantine. Numerical simulations were conducted.Results Analysis shows that the model is locally asymptomatically stable, at endemic and foreigners free equilibrium points. Without any mitigation measures, infectivity and subsequent hospitalization of the population increases while placing interstates individuals and foreigners under quarantine, decreases the chances of exposure and subsequent infection, leading to an increase in the recovery rate.Conclusion Interstate and foreign travel restrictions, in addition to quarantine, help in effectively controlling the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe third author (ENJ) is funded by UGC granted National Fellowship for Other Backward Classes (NFO-2018-19-OBC-GUJ-71790).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is not a clinical trial and no human is involved. IRB approval not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data derived from mathematical calculations done in the paper and is available to all the readers. ER -